GlassScriptPhysician profile
Inemesit Umoren
NPI 1770639676
$4,101.04
in general payments reported to CMS, 2019-2025
16 companies · $556 in 2025
The $556 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $93.90 · 2021: $1,412 · 2022: $1,142 · 2023: $137 · 2024: $37.39 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,932.51 | 2021-2022 | |
| Janssen Products, LP | $499.00 | 2019-2023 | Symtuza |
| Viiv Healthcare Company | $338.32 | 2019-2025 | Dovato |
| Abbvie INC. | $260.18 | 2021-2025 | |
| Gilead Sciences, INC. | $206.65 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $148.95 | 2019-2021 | |
| Insmed, INC. | $128.96 | 2019-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $120.16 | 2019-2021 | |
| Astellas Pharma US INC | $108.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $99.03 | 2022 | |
| Melinta Therapeutics, LLC | $97.67 | 2019-2021 | |
| Allergan, INC. | $49.77 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $39.54 | 2019-2025 | Nuzyra |
| Tetraphase Pharmaceuticals, INC. | $38.11 | 2019 | |
| Nabriva Therapeutics, Plc | $18.26 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inemesit Umoren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.